Hangzhou Tigermed Consulting Co., Ltd. (HNGZY)
USD 4.0
(0.0%)
USD 4.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 734.97 Million USD | 7.55% |
| 2022 | 683.38 Million USD | 38.89% |
| 2021 | 492.04 Million USD | 95.31% |
| 2020 | 251.93 Million USD | -14.26% |
| 2019 | 293.82 Million USD | -79.1% |
| 2018 | 1.4 Billion CNY | 79.81% |
| 2017 | 781.85 Million CNY | 42.53% |
| 2016 | 548.54 Million CNY | 0.81% |
| 2015 | 544.11 Million CNY | 23.46% |
| 2014 | 440.72 Million CNY | 733.66% |
| 2013 | 52.86 Million CNY | 37.24% |
| 2012 | 38.51 Million CNY | -5.43% |
| 2011 | 40.73 Million CNY | 68.85% |
| 2010 | 24.12 Million CNY | 4.29% |
| 2009 | 23.13 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 5.53 Billion CNY | 5.88% |
| 2024 Q3 | 5.85 Billion CNY | -7.91% |
| 2024 Q2 | 6.36 Billion CNY | 14.88% |
| 2023 Q4 | 5.22 Billion CNY | -5.33% |
| 2023 Q3 | 5.52 Billion CNY | -3.29% |
| 2023 FY | 734.97 Million USD | 7.55% |
| 2023 Q1 | 706.29 Million USD | 3.35% |
| 2023 Q2 | 5.7 Billion CNY | 708.27% |
| 2022 Q3 | 697.46 Million USD | -83.42% |
| 2022 Q4 | 683.38 Million USD | -2.02% |
| 2022 FY | 683.38 Million USD | 38.89% |
| 2022 Q1 | 3.62 Billion CNY | 15.75% |
| 2022 Q2 | 4.2 Billion CNY | 15.88% |
| 2021 Q4 | 3.13 Billion CNY | 33.19% |
| 2021 FY | 492.04 Million USD | 95.31% |
| 2021 Q1 | 270.21 Million CNY | -83.6% |
| 2021 Q2 | 305.49 Million CNY | 13.06% |
| 2021 Q3 | 2.35 Billion CNY | 670.73% |
| 2020 Q2 | 2.62 Billion CNY | 10.16% |
| 2020 Q3 | 1.3 Billion CNY | -50.33% |
| 2020 Q4 | 1.64 Billion CNY | 26.41% |
| 2020 FY | 251.93 Million USD | -14.26% |
| 2020 Q1 | 2.38 Billion CNY | 16.39% |
| 2019 Q3 | 1.31 Billion CNY | -20.98% |
| 2019 Q2 | 1.65 Billion CNY | 28.82% |
| 2019 Q4 | 2.04 Billion CNY | 56.13% |
| 2019 Q1 | 1.28 Billion CNY | -8.4% |
| 2019 FY | 293.82 Million USD | -79.1% |
| 2018 Q1 | 968.23 Million CNY | 23.84% |
| 2018 Q3 | 938.32 Million CNY | 1.5% |
| 2018 Q2 | 924.46 Million CNY | -4.52% |
| 2018 Q4 | 1.4 Billion CNY | 49.82% |
| 2018 FY | 1.4 Billion CNY | 79.81% |
| 2017 Q3 | 718.43 Million CNY | 18.92% |
| 2017 Q1 | 506.56 Million CNY | -7.65% |
| 2017 FY | 781.85 Million CNY | 42.53% |
| 2017 Q4 | 781.85 Million CNY | 8.83% |
| 2017 Q2 | 604.13 Million CNY | 19.26% |
| 2016 Q3 | 527.93 Million CNY | -6.08% |
| 2016 FY | 548.54 Million CNY | 0.81% |
| 2016 Q4 | 548.54 Million CNY | 3.9% |
| 2016 Q2 | 562.08 Million CNY | 11.57% |
| 2016 Q1 | 503.79 Million CNY | -7.41% |
| 2015 FY | 544.11 Million CNY | 23.46% |
| 2015 Q3 | 400.41 Million CNY | 103.07% |
| 2015 Q4 | 544.11 Million CNY | 35.89% |
| 2015 Q2 | 197.18 Million CNY | -10.64% |
| 2015 Q1 | 220.65 Million CNY | -49.93% |
| 2014 Q2 | 105.07 Million CNY | 7.57% |
| 2014 FY | 440.72 Million CNY | 733.66% |
| 2014 Q1 | 97.67 Million CNY | 84.77% |
| 2014 Q4 | 440.72 Million CNY | 18.39% |
| 2014 Q3 | 372.27 Million CNY | 254.28% |
| 2013 Q3 | 31.67 Million CNY | -3.16% |
| 2013 Q4 | 52.86 Million CNY | 66.92% |
| 2013 FY | 52.86 Million CNY | 37.24% |
| 2013 Q1 | 35.41 Million CNY | -8.05% |
| 2013 Q2 | 32.7 Million CNY | -7.67% |
| 2012 Q3 | 35.62 Million CNY | -1.88% |
| 2012 FY | 38.51 Million CNY | -5.43% |
| 2012 Q2 | 36.3 Million CNY | 0.0% |
| 2012 Q4 | 38.51 Million CNY | 8.14% |
| 2011 Q4 | 40.73 Million CNY | 0.0% |
| 2011 FY | 40.73 Million CNY | 68.85% |
| 2010 FY | 24.12 Million CNY | 4.29% |
| 2009 FY | 23.13 Million CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| American Bio Medica Corporation | 3.6 Million USD | -20270.656% |
| Arrayit Corporation | 7.49 Million USD | -9704.097% |
| Atlantic International Corp. | 3.82 Million USD | -19096.83% |
| Biocept, Inc. | 22.01 Million USD | -3238.815% |
| Bioqual, Inc. | 18.93 Million USD | -3780.947% |
| CardioGenics Holdings Inc | 1.79 Million USD | -40847.343% |
| DermTech, Inc. | 64.75 Million USD | -1035.006% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| HTG Molecular Diagnostics, Inc. | 12.38 Million USD | -5833.924% |
| iMD Companies, Inc. | 1.67 Million USD | -43799.549% |
| IDenta Corp. | 1.01 Million USD | -72442.809% |
| Interpace Biosciences, Inc. | 28.15 Million USD | -2510.268% |
| Integrative Health Technologies, Inc. | 297.94 Thousand USD | -246579.2% |
| InVitro International | 78.99 Thousand USD | -930363.7% |
| Lumos Diagnostics Holdings Limited | 19.72 Million USD | -3625.345% |
| Many Bright Ideas Technologies Inc. | 129.29 Thousand USD | -568337.997% |
| Medical Imaging Corp. | 9.51 Million USD | -7622.671% |
| NovelStem International Corp. | 4.2 Million USD | -17374.072% |
| Optigenex Inc. | 9.57 Million USD | -7579.475% |
| PharmChem, Inc. | 558.64 Thousand USD | -131463.094% |
| Proteome Sciences plc | 18.48 Million USD | -3875.181% |
| Response Genetics, Inc | 15.86 Million USD | -4532.087% |
| Rennova Health, Inc. | 49.66 Million USD | -1379.792% |
| RushNet, Inc. | 6.23 Million USD | -11680.321% |
| ScreenPro Security Inc. | 1.6 Million USD | -45818.983% |
| Stella Diagnostics Inc. | 18 Million USD | -3981.959% |
| StageZero Life Sciences Ltd. | 8.2 Million USD | -8858.731% |
| Todos Medical Ltd. | 50.15 Million USD | -1365.345% |